Plus Therapeutics, Inc. (NASDAQ:PSTV) Receives Average Rating of “Moderate Buy” from Analysts

Plus Therapeutics, Inc. (NASDAQ:PSTV) has been given a consensus recommendation of “Moderate Buy” by the seven research firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $7.25.

A number of research analysts have recently issued reports on PSTV shares. HC Wainwright restated a “buy” rating and issued a $2.00 price target on shares of Plus Therapeutics in a research report on Wednesday, November 26th. Ascendiant Capital Markets dropped their price objective on shares of Plus Therapeutics from $21.00 to $19.00 and set a “buy” rating on the stock in a research note on Friday, November 21st. D Boral Capital raised shares of Plus Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, September 3rd. D. Boral Capital reaffirmed a “buy” rating and set a $5.00 target price on shares of Plus Therapeutics in a report on Thursday, December 11th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Plus Therapeutics in a research report on Wednesday, October 8th.

Institutional Investors Weigh In On Plus Therapeutics

A number of hedge funds have recently added to or reduced their stakes in PSTV. Jane Street Group LLC acquired a new position in shares of Plus Therapeutics during the second quarter valued at $41,000. Susquehanna International Group LLP bought a new stake in Plus Therapeutics in the 3rd quarter valued at about $46,000. Scientech Research LLC acquired a new position in Plus Therapeutics during the 3rd quarter valued at about $100,000. Finally, Altium Capital Management LLC acquired a new position in Plus Therapeutics during the 3rd quarter valued at about $628,000. 3.28% of the stock is currently owned by institutional investors.

Plus Therapeutics Trading Up 1.4%

Shares of PSTV opened at $0.58 on Friday. Plus Therapeutics has a 52 week low of $0.16 and a 52 week high of $2.31. The firm has a market cap of $79.70 million, a price-to-earnings ratio of -0.30 and a beta of 0.82. The stock has a 50 day moving average of $0.58 and a 200-day moving average of $0.52.

Plus Therapeutics (NASDAQ:PSTV) last announced its quarterly earnings data on Thursday, October 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.02). The company had revenue of $1.40 million during the quarter, compared to analysts’ expectations of $1.50 million. On average, sell-side analysts predict that Plus Therapeutics will post -2.3 earnings per share for the current fiscal year.

About Plus Therapeutics

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.